On Sierra World Equity Review website posted today !
With Div cut expected, stock is expected to move towards a range of 15% to 20% div which should move the stock in the $15 to $17 range
idiot, next week is FDA NDA acceptance, are you really that dense ? Then EU 120 days questions in Feb
Pretty obvious that $5 options are going to expire worthless this month, perhaps the same for Jan too. But expect buying to pick up in Jan as it gets closer to PDUFA, some tax losses are being taken this month I am sure
Google it the topic is "No serious heart risks' linked to smoking cessation therapies" Medical News Today
Looks like Dec 15 was a non-event, but the stock still stuck in the mud ...
just about 2 weeks more for buyout to be completed which Scott predicted. Shareholders can start counting their blessings now
Really have you heard of VVUS weight loss drug ? It was The first one approved for weight loss last year called Qysmia, and yes it is a Combo like Contrave ! Truly are you really that stupid or just pretending to be ?
The only thing doubling from here is the stock price. FDA wanted Orex to demonstrate a less than 2 fold risk going forward, Orex did that. Does not mean Contrave has 1.9 times the risk, in fact the risk could be less than 1 or less than placebo as Contrave could in fact decrease cardiovascular risk by causing weight loss. Yahoo target is $11.38 for a reason. FDA agreed to submit the application early and accept the data 2 months later just goes to show how "eager" FDA is to review the drug. With VVUS drug Qsymia(also a combo like Contave) and ARNA's Belviq approved with far less data, Contrave approval is slam dunk for approval. As per Zacks, European approval is very likely too, the only weight loss drug to do so could blast the price up more.
It is time to get long with 4 catalysts not too far away, this is about the lowest the pps will get.
Sentiment: Strong Buy
Less than double was FDA's requirement for approval. The data shows less than double risk, it could well be equal or due to weight loss even less than placebo for Contrave. So this interim data is surely positive going forward.
The drug is a almost guaranteed approval, European approval is likely too. Lot of good catalysts coming up. It is time to accumulate before run up.